Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Main Capital in connection with its acquisition of Blika Solutions AB
Mandate

Vinge has advised Main Capital in connection with its acquisition of Blika Solutions AB

April 06, 2022 Employment and Benefits M&A Intellectual Property IT, Telecommunications and Outsourcing Commercial Agreements

Blika provides a modular, best-of-breed SaaS system which allows companies to monitor legal structures ensuring proper governance and compliance. The platform helps enterprises to comply with tax, legal and transfer pricing regulations such as DAC6 and IFRIC 23.

Blika is headquartered in Stockholm with additional offices in Kalmar and Oskarshamn and has a large client base comprising European and global multinational businesses including Fortune 500 companies.

Vinge’s team consisted of Filip Öhrner, Manne Bergström, Egil Svensson (M&A), Veronika Garemark, Elin Broman (Employment), Rebecka Målquist (IP), Lisa Hörnqvst, Karolina Fuhrman (Commercial Agreements, IT & GDPR) and Jessica Henning (VDR Assistant).

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026